the first topical treatment specifically approved for chronic hand eczema (CHE). The launch of pan-JAK inhibitor Anzupgo (delgocitinib) comes after the European Commission approved the drug last ...

a treatment for chronic hand eczema (CHE) considered to be its top pipeline prospect. The EMA's human medicines committee, the CHMP, delivered a positive opinion on the drug at its meeting ahead ...

Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...

Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...

A blockbuster drug is a therapy that generates at least $1 billion in sales. Clarivate’s Drugs to Watch 2025 report includes ...

Coping with eczema can be a challenge. While it is not a life-threatening or dangerous medical illness, eczema is a skin condition that can interfere with your happiness and quality of life. This ...

Learn about rheumatoid vasculitis, neutrophilic dermatoses, and other rheumatoid arthritis rashes, their symptoms, and when ...

Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...

Based on empirical criteria, eczema was identified in 12,424 individuals (10.7% of the total weighted population, 58% of the symptomatic subpopulation), and AD was identified in 6,931 individuals ...

Discover why Incyte's strong growth trajectory and upcoming product launches make it an attractive investment with a ...

With 13 states offering coverage, it’s already a $3.9 billion cost. Some state officials say reducing obesity will save programs money in the long run.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...